ClinicalTrials.gg
CompletedNCT00457002ADOPTUpdated Dec 8, 2015Results posted

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

A Phase 3 interventional study of Apixaban and Enoxaparin in Venous Thrombosis and Pulmonary Embolism, sponsored by Bristol-Myers Squibb. Completed at 297 sites in 35 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-12-08.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,758
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.

Enrollment
Largest of 26
6,758 · median 445
Started
2007
with 1 other
Phase 3
10 of 26
1 open now
Registered
4th of 26
by date
Lead sponsor
6 of 26
Bristol-Myers Squibb

Among the 26 studies testing apixaban in Venous Thrombosis, this one has the largest enrollment, is one of 2 that started in 2007, is one of 10 in phase 3, and was the 4th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing apixaban in Venous Thrombosis, or all of them as a file.
02

Study summary

The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur within patients hospitalized for acute medical illness, and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. The safety of apixaban will also be studied.

03

Conditions studied

  • Venous Thrombosis
  • Pulmonary Embolism

Keywords

  • Prevention of deep vein thrombosis and pulmonary embolism with acutely ill hospitalized patients
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • men and non-pregnant, non-breastfeeding women
  • 40 years or older
  • hospitalized with congestive heart failure or acute respiratory failure
  • infection (without septic shock)
  • acute rheumatic disorder
  • inflammatory bowel disease

Exclusion criteria

Exclusion Criteria:

  • patients with venous thromboembolism (VTE)
  • active bleeding or at high risk of bleeding
  • unable to take oral medication
  • with diseases requiring ongoing treatment with anticoagulants or antiplatelets other than aspirin at a dose ≤ 165 mg/day.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
6,758 participants (actual)

Study arms

  • Experimental
    Arm 1

    While hospitalized, Apixaban plus Placebo Apixaban (Tablets, Oral, 2.5 mg), Placebo (Syringes, SC) After hospital discharge, Apixaban Apixaban (Tablets, Oral, 2.5 mg)

    Drug: Apixaban

  • Active comparator
    Arm 2

    While hospitalized, Enoxaparin plus Placebo Enoxaparin (Syringes, SC, 40 mg), Placebo (Tablets, Oral) After hospital discharge: Placebo Placebo (Tablets, Oral)

    Drug: Enoxaparin

Interventions

  • Apixaban: Twice daily, 30 days Placebo: Once daily, 6-14 days

    Also known as: BMS-562247

  • Enoxaparin: Once daily, 6-14 days Placebo: Twice daily, 30 days

06

What researchers measure

Primary outcomes

  1. Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population

    VTE: nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE could not be excluded as a cause. Intended Treatment Period=period that started on day of randomization: period ended (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; period ended (for not treated) 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. All efficacy events were adjudicated by the Independent Central Adjudication Committee (ICAC). Event rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  2. Incidence of Major Bleeding During the Treatment Period in Treated Participants

    Major bleeding was adjudicated by an ICAC using criteria from the International Society on Thrombosis and Hemostasis (ISTH) and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or bleeding in a critical site or bleeding which is fatal. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Day 1, first dose of study drug, to last dose of study drug plus 2 days

  3. Incidence of Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants

    Bleeding was adjudicated by an ICAC using criteria from the ISTH. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis, if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for bleeding endpoints. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Day 1, first dose of study drug, to last dose of study drug plus 2 days

  4. Incidence of Composite of Major or Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants

    Bleeding was adjudicated by an ICAC using criteria from the ISTH. Major bleeding: acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or bleeding in a critical site or bleeding which is fatal. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage; rectal blood loss. Treatment Period=onset from first dose of study drug through 2 days after last dose of study drugs. Incidence: Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Day 1, first dose of study drug, to last dose of study drug plus 2 days

  5. Incidence of All Bleeding During the Treatment Period in Treated Participants

    Bleeding was adjudicated by an ICAC using criteria from the ISTH. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs, for bleeding endpoints. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Day 1, first dose of drug to last dose of drug plus 2 days

Secondary outcomes

  1. Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Key Secondary Efficacy Evaluable Participants

    Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Key Secondary Efficacy population: all who received at least 1 dose of parenteral study drug and: (those without suspected VTE events during Parenteral Treatment) had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or (those with suspected VTE events during Parenteral Treatment) had those suspected VTE events adjudicated as non-events, and had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or had an adjudicated total VTE during Parenteral Treatment; or had an adjudicated VTE-related death during Parenteral Treatment. Event rate (%): n/N\*100 (n=number with observation; N=total secondary efficacy evaluable participants).

    Time frame: Day 1 to last dose of parenteral study drug plus 1 day

  2. Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Secondary Efficacy Evaluable Participants

    Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Secondary Efficacy Evaluable includes those who had an adjudicated, evaluable ultrasound at end of parenteral treatment and for those with a suspected symptomatic event, the result of the adjudication for the symptomatic event was not inadequate; or those with an adjudicated event that was part of the composite endpoint.. Event rate (%): n/N\*100 (n=number with observation; N=total secondary efficacy evaluable participants).

    Time frame: Day 1 to last dose of parenteral study drug plus 1 day

  3. Incidence of Adjudicated Total VTE or All-Cause Death With Onset During the Intended Treatment Period

    Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal (N-F) PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. All-Cause Death (A-C Death). Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  4. Incidence of Adjudicated Proximal DVT, Non-Fatal PE or All-Cause Death With Onset During the Intended Treatment Period

    Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  5. Incidence of Adjudicated Proximal DVT, Non-Fatal PE or VTE-Related Death, With Onset During the Intended Treatment Period

    Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  6. Incidence of Adjudicated VTE-Related Death With Onset During the Intended Treatment Period in Randomized Participants

    Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  7. Incidence of Adjudicated Symptomatic VTE or All-Cause Death With Onset During the Intended Treatment Period

    Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  8. Symptomatic Adjudicated VTE or VTE-Related Death With Onset During the Intended Treatment Period

    Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  9. Incidence of All VTE or Major Bleeding or All-Cause Death During the Intended Treatment Period

    Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  10. Incidence of Adjudicated PE With Onset During the Intended Treatment Period

    Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. PE: non-fatal or fatal. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  11. Incidence of Adjudicated Non-Fatal PE With Onset During the Intended Treatment Period

    Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  12. Incidence of Adjudicated Symptomatic DVT With Onset During the Intended Treatment Period

    Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  13. Incidence of Adjudicated Proximal DVT With Onset During the Intended Treatment Period

    Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  14. Incidence of Adjudicated Symptomatic Distal DVT With Onset During the Intended Treatment Period

    Events were adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  15. Incidence of Adjudicated Symptomatic Proximal DVT With Onset During the Intended Treatment Period

    Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  16. Incidence of Adjudicated Asymptomatic Proximal DVT With Onset During the Intended Treatment Period

    A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

    Time frame: Intended Treatment Period

  17. Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Deaths, and Discontinuations Due to AEs During the Treatment Period in Treated Participants

    Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for AEs, and 30 days after last dose of study drugs for SAEs and deaths.

    Time frame: Day 1, first dose of study drug, to last dose of study drug plus 2 days (AEs), plus 30 days (SAEs, Deaths)

  18. Mean Change From Baseline in Diastolic Blood Pressure in Treated Participants During Treatment Period

    Diastolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken with the participant either sitting, standing, or supine.

    Time frame: Day 1 to last dose of study drug plus 2 days

  19. Mean Change From Baseline in Systolic Blood Pressure in Treated Participants During Treatment Period

    Systolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken either sitting, standing, or supine.

    Time frame: Day 1 to last dose of study drug plus 2 days

  20. Mean Change From Baseline in Heart Rate in Treated Participants

    Heart Rate was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Heart rate was measured in beats per minute (bpm) and could have been taken with participants either sitting, standing, or supine.

    Time frame: Day 1 to last dose of study drug plus 2 days

  21. Number of Participants With Marked Abnormalities in Hematology Laboratory Tests During Treatment Period in Treated Participants

    Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). Absolute (Abs). Hemoglobin: \>2 g/dL decrease compared to PreRx value or value \<=8 g/dL; Hematocrit: \<0.75\*PreRx; Erythrocytes: \<0.75\*PreRx c/µL; Leukocytes: \<0.75\*LLN or \> 1.25\*ULN, if PreRx \<LLN then use \<0.8\*PreRx or \>ULN, if PreRx \>ULN then use \>1.2\*PreRx or \< LLN; Platelet count: \< 100\*10\^9 c/L; ANC: \< 1.00\*10\^3 c/µL; Abs eosinophils: \> 0.75\*10\^3 c/µL; Abs Basophils: \> 400/MM\^3; Abs Monocytes \> 2000/MM\^3; Abs Lymphocytes: \< 0.750\*10\*3 c/ µL or \> 7.5\*10\^3 c/ µL. Samples were obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.

    Time frame: Day 1 to last dose of study drug plus 2 days

  22. Number of Participants With Marked Abnormalities in Electrolyte Laboratory Tests During Treatment Period in Treated Participants

    Bicarbonate milliequivalents/Liter (mEq/L) Low/High: \< 0.75\*LLN or \> 1.25\*ULN, or if PreRx \< LLN then use \< 0.75\* PreRx or \> ULN if PreRx \> ULN then use \> 1.25\*PreRx or \< LLN; Serum Calcium mg/dL Low/High: \< 0.8\*LLN or \> 1.2\*ULN, or if PreRx \< LLN then use \< 0.75\*PreRx or \> ULN if PreRx \> ULN then use \> 1.25\*PreRx or \< LLN; Serum Chloride mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use \< 0.9\*PreRx or \> ULN if PreRx \> ULN then use \> 1.1\*PreRx or \< LLN; Serum Potassium mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use \< 0.9\*PreRx or \> ULN if PreRx \> ULN then use \> 1.1\*PreRx or \< LLN; Serum Sodium mEq/L: \< 0.95\*LLN or \> 1.05\*ULN, or if PreRx \< LLN then use \< 0.95\*PreRx or \> ULN if PreRx \> ULN then use \> 1.05\*PreRx or \< LLN. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.

    Time frame: Day 1 to last dose of study drug plus 2 days

  23. Number of Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests During the Treatment Period in Treated Participants

    Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL \> 1.5\*ULN; Creatinine mg/dL: \> 1.5\*ULN; Alanine aminotransferase (ALT) U/L: \> 3\*ULN; Aspartate aminotransferase (AST) U/L: \> 3\*ULN; Alkaline phosphatase U/L: \> 2\*ULN; Bilirubin Direct mg/dL: \> 1.5\*ULN; Bilirubin Total mg/dL: \> 2\*ULN. Samples for laboratories obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.

    Time frame: Day 1 to last dose of study drug plus 2 days

  24. Number of Participants With Marked Abnormalities in Glucose, Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests During the Treatment Period in Treated Participants

    Creatine kinase High: \>5\*ULN Units/Liter (U/L); Total Protein High/Low: \< 0.9 \*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use 0.9\* PreRx or \> ULN if PreRx \> ULN then use 1.1 \*PreRx or \<LLN; Uric acid High: \> 1.5\* ULN, or if PreRx \> ULN then use \> 2 \*PreRx. Glucose Fasting: \<0.9\*LLN or \> 1.5\*ULN or if PreRx \< LLN then use \< 0.8\*PreRx or \> ULN, if PreRx \> ULN then use \>2.0\*PreRx. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) ± 2days.

    Time frame: Day 1 to last dose of study drug plus 2 days

  25. Incidence of Events of Special Interest of Adjudicated Myocardial Infarction, Stroke, and Thrombocytopenia During the Treatment Period in Treated Participants

    Events of Special Interest include: adjudicated thrombocytopenia, adjudicated myocardial infarction (MI), adjudicated stroke, and adjudicated MI or stroke. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants). Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs.

    Time frame: Day 1 to last dose of study drug plus 2 days

  26. Number of Participants With Events of Special Interest for Liver Function and Neurology During Treatment Period in Treated Participants With Available Measurements

    Special interest include: liver function test increases, AEs related to liver function, and neurologic AEs. Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drug when summarizing AEs and through 30 days after the last dose when summarizing SAEs.

    Time frame: Day 1 to last dose of study drug plus 2 days (AEs) and plus 30 days (SAEs)

  27. Number of Participants With Liver-Related Elevations During the Treatment Period in Treated Participants

    Liver function tests: Alanine aminotransferase (ALT) U/L; Aspartate aminotransferase (AST) U/L; Alkaline phosphatase U/L; Total Bilirubin (TBili) mg/dL. Elevations consist of \>3\*Upper Limit of Normal (ULN) for ALT and AST and elevation of \>2\*ULN for Bilirubin.

    Time frame: Day 1 to last dose of study drug plus 2 days

07

Results

Posted May 20, 2014

Participant flow

First patient, first visit was June 2007 and last patient, last visit was May 2011. Acutely ill patients who had been hospitalized and had an expected hospitalization of an additional 3 or more days after randomization were enrolled.

Participant flow — Overall Study
MilestoneApixaban 2.5 mg OralEnoxaparin 40 mg Subcutaneous
Started32553273
Completed24422516
Not completed813757
Withdrew: Death4047
Withdrew: Adverse event284260
Withdrew: Withdrawal by subject299271
Withdrew: Lost to follow-up7271
Withdrew: Poor/non-compliance4633
Withdrew: No longer met criteria4137
Withdrew: Administrative reason by sponsor10
Withdrew: Non-specified2938
Withdrew: Treated for 1 day; missing status/reason10

Outcome measures

PrimaryIncidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population

VTE: nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE could not be excluded as a cause. Intended Treatment Period=period that started on day of randomization: period ended (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; period ended (for not treated) 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. All efficacy events were adjudicated by the Independent Central Adjudication Committee (ICAC). Event rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event rate (%)
Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population
Event rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population2.71 (2.11 to 3.49)3.06 (2.43 to 3.86)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Mantel Haenszel · p = 0.4364 · Risk ratio (rr): 0.87 · 95% CI 0.62 to 1.23
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.39 · 95% CI -1.37 to 0.59
SecondaryIncidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Key Secondary Efficacy Evaluable Participants

Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Key Secondary Efficacy population: all who received at least 1 dose of parenteral study drug and: (those without suspected VTE events during Parenteral Treatment) had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or (those with suspected VTE events during Parenteral Treatment) had those suspected VTE events adjudicated as non-events, and had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or had an adjudicated total VTE during Parenteral Treatment; or had an adjudicated VTE-related death during Parenteral Treatment. Event rate (%): n/N\*100 (n=number with observation; N=total secondary efficacy evaluable participants).

Time frame:
Day 1 to last dose of parenteral study drug plus 1 day
Reported as:
Number · Event rate (%)
Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Key Secondary Efficacy Evaluable Participants
Event rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Key Secondary Efficacy Evaluable Participants1.73 (1.28 to 2.33)1.61 (1.18 to 2.19)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 1.06 · 95% CI 0.69 to 1.63
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): 0.10 · 95% CI -0.61 to 0.81
SecondaryIncidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Secondary Efficacy Evaluable Participants

Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Secondary Efficacy Evaluable includes those who had an adjudicated, evaluable ultrasound at end of parenteral treatment and for those with a suspected symptomatic event, the result of the adjudication for the symptomatic event was not inadequate; or those with an adjudicated event that was part of the composite endpoint.. Event rate (%): n/N\*100 (n=number with observation; N=total secondary efficacy evaluable participants).

Time frame:
Day 1 to last dose of parenteral study drug plus 1 day
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Secondary Efficacy Evaluable Participants
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Secondary Efficacy Evaluable Participants1.66 (1.22 to 2.28)1.51 (1.09 to 2.10)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 1.09 · 95% CI 0.70 to 1.71
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): 0.14 · 95% CI -0.57 to 0.85
SecondaryIncidence of Adjudicated Total VTE or All-Cause Death With Onset During the Intended Treatment Period

Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal (N-F) PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. All-Cause Death (A-C Death). Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated Total VTE or All-Cause Death With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Total VTE or All-Cause Death With Onset During the Intended Treatment Period6.44 (5.51 to 7.53)6.63 (5.69 to 7.71)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 0.96 · 95% CI 0.78 to 1.20
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.24 · 95% CI -1.65 to 1.17
SecondaryIncidence of Adjudicated Proximal DVT, Non-Fatal PE or All-Cause Death With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated Proximal DVT, Non-Fatal PE or All-Cause Death With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Proximal DVT, Non-Fatal PE or All-Cause Death With Onset During the Intended Treatment Period6.44 (5.51 to 7.53)6.50 (5.58 to 7.58)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 0.98 · 95% CI 0.79 to 1.22
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.12 · 95% CI -1.52 to 1.29
SecondaryIncidence of Adjudicated Proximal DVT, Non-Fatal PE or VTE-Related Death, With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated Proximal DVT, Non-Fatal PE or VTE-Related Death, With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Proximal DVT, Non-Fatal PE or VTE-Related Death, With Onset During the Intended Treatment Period2.71 (2.11 to 3.49)2.93 (2.32 to 3.72)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 0.91 · 95% CI 0.65 to 1.29
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.26 · 95% CI -1.23 to 0.71
SecondaryIncidence of Adjudicated VTE-Related Death With Onset During the Intended Treatment Period in Randomized Participants

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated VTE-Related Death With Onset During the Intended Treatment Period in Randomized Participants
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated VTE-Related Death With Onset During the Intended Treatment Period in Randomized Participants0.06 (0.00 to 0.24)0.09 (0.02 to 0.29)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 0.68 · 95% CI 0.11 to 4.05
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.03 · 95% CI -0.16 to 0.10
SecondaryIncidence of Adjudicated Symptomatic VTE or All-Cause Death With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated Symptomatic VTE or All-Cause Death With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Symptomatic VTE or All-Cause Death With Onset During the Intended Treatment Period3.11 (2.56 to 3.77)3.46 (2.88 to 4.14)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 0.89 · 95% CI 0.68 to 1.16
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.38 · 95% CI -1.25 to 0.48
SecondarySymptomatic Adjudicated VTE or VTE-Related Death With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Symptomatic Adjudicated VTE or VTE-Related Death With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Symptomatic Adjudicated VTE or VTE-Related Death With Onset During the Intended Treatment Period0.40 (0.23 to 0.69)0.80 (0.54 to 1.17)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 0.50 · 95% CI 0.26 to 0.96
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.40 · 95% CI -0.78 to -0.03
SecondaryIncidence of All VTE or Major Bleeding or All-Cause Death During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of All VTE or Major Bleeding or All-Cause Death During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of All VTE or Major Bleeding or All-Cause Death During the Intended Treatment Period7.16 (6.18 to 8.29)6.83 (5.88 to 7.93)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 1.04 · 95% CI 0.84 to 1.28
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): 0.28 · 95% CI -1.18 to 1.73
SecondaryIncidence of Adjudicated PE With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. PE: non-fatal or fatal. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated PE With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated PE With Onset During the Intended Treatment Period0.22 (0.10 to 0.46)0.24 (0.12 to 0.50)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 0.88 · 95% CI 0.32 to 2.43
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.03 · 95% CI -0.26 to 0.20
SecondaryIncidence of Adjudicated Non-Fatal PE With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated Non-Fatal PE With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Non-Fatal PE With Onset During the Intended Treatment Period0.22 (0.10 to 0.46)0.24 (0.12 to 0.50)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 0.88 · 95% CI 0.32 to 2.43
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.03 · 95% CI -0.26 to 0.20
SecondaryIncidence of Adjudicated Symptomatic DVT With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated Symptomatic DVT With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Symptomatic DVT With Onset During the Intended Treatment Period0.15 (0.06 to 0.37)0.49 (0.30 to 0.80)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 0.31 · 95% CI 0.11 to 0.83
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.34 · 95% CI -0.62 to -0.07
SecondaryIncidence of Adjudicated Proximal DVT With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated Proximal DVT With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Proximal DVT With Onset During the Intended Treatment Period2.40 (1.84 to 3.14)2.50 (1.94 to 3.24)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 0.94 · 95% CI 0.65 to 1.37
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.14 · 95% CI -1.04 to 0.76
SecondaryIncidence of Adjudicated Symptomatic Distal DVT With Onset During the Intended Treatment Period

Events were adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated Symptomatic Distal DVT With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Symptomatic Distal DVT With Onset During the Intended Treatment Period0.00 (0.00 to 0.15)0.15 (0.06 to 0.37)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.15 · 95% CI -0.29 to -0.02
SecondaryIncidence of Adjudicated Symptomatic Proximal DVT With Onset During the Intended Treatment Period

Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated Symptomatic Proximal DVT With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Symptomatic Proximal DVT With Onset During the Intended Treatment Period0.15 (0.06 to 0.37)0.37 (0.20 to 0.65)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 0.41 · 95% CI 0.14 to 1.16
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): -0.22 · 95% CI -0.47 to 0.03
PrimaryIncidence of Major Bleeding During the Treatment Period in Treated Participants

Major bleeding was adjudicated by an ICAC using criteria from the International Society on Thrombosis and Hemostasis (ISTH) and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or bleeding in a critical site or bleeding which is fatal. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Day 1, first dose of study drug, to last dose of study drug plus 2 days
Reported as:
Number · Event Rate (%)
Incidence of Major Bleeding During the Treatment Period in Treated Participants
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Major Bleeding During the Treatment Period in Treated Participants0.47 (0.28 to 0.79)0.19 (0.08 to 0.42)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Mantel Haenszel · p = 0.0437 (The Mantel-Haenszel test stratified by the stratification factors will be used at the one-sided alpha=0.025 level.) · Adjusted difference of event rates: 0.29 · 95% CI 0.01 to 0.57
PrimaryIncidence of Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants

Bleeding was adjudicated by an ICAC using criteria from the ISTH. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis, if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for bleeding endpoints. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Day 1, first dose of study drug, to last dose of study drug plus 2 days
Reported as:
Number · Event Rate (%):
Incidence of Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants
Event Rate (%):Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants2.26 (1.80 to 2.84)1.90 (1.48 to 2.43)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Adjusted difference of event rates: 0.36 · 95% CI -0.33 to 1.06
PrimaryIncidence of Composite of Major or Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants

Bleeding was adjudicated by an ICAC using criteria from the ISTH. Major bleeding: acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or bleeding in a critical site or bleeding which is fatal. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage; rectal blood loss. Treatment Period=onset from first dose of study drug through 2 days after last dose of study drugs. Incidence: Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Day 1, first dose of study drug, to last dose of study drug plus 2 days
Reported as:
Number · Event Rate (%)
Incidence of Composite of Major or Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Composite of Major or Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants2.67 (2.16 to 3.29)2.08 (1.64 to 2.64)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Adjustted difference of event rates: 0.59 · 95% CI -016 to 1.33
PrimaryIncidence of All Bleeding During the Treatment Period in Treated Participants

Bleeding was adjudicated by an ICAC using criteria from the ISTH. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs, for bleeding endpoints. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Day 1, first dose of drug to last dose of drug plus 2 days
Reported as:
Number · Event Rate (%)
Incidence of All Bleeding During the Treatment Period in Treated Participants
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of All Bleeding During the Treatment Period in Treated Participants7.73 (6.85 to 8.71)6.81 (5.99 to 7.73)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Adjusted difference of event rates: 0.87 · 95% CI -0.40 to 2.14
SecondaryIncidence of Adjudicated Asymptomatic Proximal DVT With Onset During the Intended Treatment Period

A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).

Time frame:
Intended Treatment Period
Reported as:
Number · Event Rate (%)
Incidence of Adjudicated Asymptomatic Proximal DVT With Onset During the Intended Treatment Period
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
Incidence of Adjudicated Asymptomatic Proximal DVT With Onset During the Intended Treatment Period2.36 (1.80 to 3.09)2.12 (1.60 to 2.80)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk ratio (rr): 1.10 · 95% CI 0.74 to 1.61
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Risk difference (rd): 0.20 · 95% CI -0.66 to 1.07
SecondaryNumber of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Deaths, and Discontinuations Due to AEs During the Treatment Period in Treated Participants

Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for AEs, and 30 days after last dose of study drugs for SAEs and deaths.

Time frame:
Day 1, first dose of study drug, to last dose of study drug plus 2 days (AEs), plus 30 days (SAEs, Deaths)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Deaths, and Discontinuations Due to AEs During the Treatment Period in Treated Participants
participantsApixaban 2.5 mgEnoxaparin 40 mg
AEs18711910
SAEs611601
Bleeding AEs244221
Discontinuations Due to AE290262
Deaths131133
SecondaryMean Change From Baseline in Diastolic Blood Pressure in Treated Participants During Treatment Period

Diastolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken with the participant either sitting, standing, or supine.

Time frame:
Day 1 to last dose of study drug plus 2 days
Reported as:
Mean · mmHg
Mean Change From Baseline in Diastolic Blood Pressure in Treated Participants During Treatment Period
mmHgApixaban 2.5 mgEnoxaparin 40 mg
Day of Discharge from Hospital (N=1607, 1625)-1.0 ± 12.69-0.4 ± 12.32
Day 30 of Treatment + 2 (N=2227,2301)0.0 ± 12.91-0.5 ± 12.78
SecondaryMean Change From Baseline in Systolic Blood Pressure in Treated Participants During Treatment Period

Systolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken either sitting, standing, or supine.

Time frame:
Day 1 to last dose of study drug plus 2 days
Reported as:
Mean · mmHg
Mean Change From Baseline in Systolic Blood Pressure in Treated Participants During Treatment Period
mmHgApixaban 2.5 mgEnoxaparin 40 mg
Discharge from Hospital (N=1607, 1625)-3.0 ± 19.12-2.4 ± 19.80
Day 30 of Treatment + 2 (N=2227, 2301)-2.3 ± 19.79-2.9 ± 20.61
SecondaryMean Change From Baseline in Heart Rate in Treated Participants

Heart Rate was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Heart rate was measured in beats per minute (bpm) and could have been taken with participants either sitting, standing, or supine.

Time frame:
Day 1 to last dose of study drug plus 2 days
Reported as:
Mean · bpm
Mean Change From Baseline in Heart Rate in Treated Participants
bpmApixaban 2.5 mgEnoxaparin 40 mg
Hospital Discharge (N=1606,1622)-5.4 ± 14.08-5.1 ± 14.07
Day 30 of treatment (N=2225,2299)-4.0 ± 15.62-4.3 ± 14.83
SecondaryNumber of Participants With Marked Abnormalities in Hematology Laboratory Tests During Treatment Period in Treated Participants

Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). Absolute (Abs). Hemoglobin: \>2 g/dL decrease compared to PreRx value or value \<=8 g/dL; Hematocrit: \<0.75\*PreRx; Erythrocytes: \<0.75\*PreRx c/µL; Leukocytes: \<0.75\*LLN or \> 1.25\*ULN, if PreRx \<LLN then use \<0.8\*PreRx or \>ULN, if PreRx \>ULN then use \>1.2\*PreRx or \< LLN; Platelet count: \< 100\*10\^9 c/L; ANC: \< 1.00\*10\^3 c/µL; Abs eosinophils: \> 0.75\*10\^3 c/µL; Abs Basophils: \> 400/MM\^3; Abs Monocytes \> 2000/MM\^3; Abs Lymphocytes: \< 0.750\*10\*3 c/ µL or \> 7.5\*10\^3 c/ µL. Samples were obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.

Time frame:
Day 1 to last dose of study drug plus 2 days
Reported as:
Number · participants
Number of Participants With Marked Abnormalities in Hematology Laboratory Tests During Treatment Period in Treated Participants
participantsApixaban 2.5 mgEnoxaparin 40 mg
Hemoglobin >2 g/dL decrease (N=2835, 2871)13398
Hematocrit <0.75*PreRx (N=2688, 2722)2317
Platelet Count < 100*10^9 c/L (N=2761, 2799)97
Erythrocytes <0.75*PreRx c/µL (N=2697, 2730)2816
Leukocytes <0.75*LLN (N= 2835, 2869)6455
Leukocytes > 1.25*ULN (N=2835, 2869)331283
Abs Eosinophils > 0.75*10^3 c/µL (N=20, 24)11
Abs Lymphocytes < 0.750*10*3 c/ µL (N=20, 24)42
Abs Monocytes > 2000/MM^3 (N= 19, 25)10
SecondaryNumber of Participants With Marked Abnormalities in Electrolyte Laboratory Tests During Treatment Period in Treated Participants

Bicarbonate milliequivalents/Liter (mEq/L) Low/High: \< 0.75\*LLN or \> 1.25\*ULN, or if PreRx \< LLN then use \< 0.75\* PreRx or \> ULN if PreRx \> ULN then use \> 1.25\*PreRx or \< LLN; Serum Calcium mg/dL Low/High: \< 0.8\*LLN or \> 1.2\*ULN, or if PreRx \< LLN then use \< 0.75\*PreRx or \> ULN if PreRx \> ULN then use \> 1.25\*PreRx or \< LLN; Serum Chloride mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use \< 0.9\*PreRx or \> ULN if PreRx \> ULN then use \> 1.1\*PreRx or \< LLN; Serum Potassium mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use \< 0.9\*PreRx or \> ULN if PreRx \> ULN then use \> 1.1\*PreRx or \< LLN; Serum Sodium mEq/L: \< 0.95\*LLN or \> 1.05\*ULN, or if PreRx \< LLN then use \< 0.95\*PreRx or \> ULN if PreRx \> ULN then use \> 1.05\*PreRx or \< LLN. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.

Time frame:
Day 1 to last dose of study drug plus 2 days
Reported as:
Number · participants
Number of Participants With Marked Abnormalities in Electrolyte Laboratory Tests During Treatment Period in Treated Participants
participantsApixaban 2.5 mgEnoxaparin 40 mg
Calcium < 0.8*LLN (N=2861, 2893)68
Calcium > 1.2*ULN (N=2861, 2893)33
Chloride < 0.9*LLN (N=2861, 2886)2525
Chloride > 1.1*ULN (N=2861, 2886)51
Bicarbonate < 0.75*LLN (N=2831, 2855)56
Bicarbonate > 1.25*ULN (N=2831, 2855)64
Potassium < 0.9*LLN (N=2851, 2878)6158
Potassium > 1.1*ULN (N=2851, 2878)140137
Sodium < 0.95*LLN (N=2862, 2888)2325
Sodium > 1.05*ULN (N=2862, 2888)96
SecondaryNumber of Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests During the Treatment Period in Treated Participants

Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL \> 1.5\*ULN; Creatinine mg/dL: \> 1.5\*ULN; Alanine aminotransferase (ALT) U/L: \> 3\*ULN; Aspartate aminotransferase (AST) U/L: \> 3\*ULN; Alkaline phosphatase U/L: \> 2\*ULN; Bilirubin Direct mg/dL: \> 1.5\*ULN; Bilirubin Total mg/dL: \> 2\*ULN. Samples for laboratories obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.

Time frame:
Day 1 to last dose of study drug plus 2 days
Reported as:
Number · participants
Number of Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests During the Treatment Period in Treated Participants
participantsApixaban 2.5 mgEnoxaparin 40 mg
Alkaline phosphatase U/L > 2*ULN(N=2866, 2895)3547
ALT U/L > 3*ULN (N=2827, 2861)2333
AST U/L > 3*ULN (N=2831, 2863)2429
Bilirubin Direct mg/dL > 1.5*ULN (N=2782, 2821)123106
Bilirubin Total mg/dL > 2*ULN (N=2853, 2884)1715
BUN mg/dL > 1.5*ULN (N=2864, 2891)194188
Creatinine mg/dL > 1.5*ULN (N=2862, 2892)150156
SecondaryNumber of Participants With Marked Abnormalities in Glucose, Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests During the Treatment Period in Treated Participants

Creatine kinase High: \>5\*ULN Units/Liter (U/L); Total Protein High/Low: \< 0.9 \*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use 0.9\* PreRx or \> ULN if PreRx \> ULN then use 1.1 \*PreRx or \<LLN; Uric acid High: \> 1.5\* ULN, or if PreRx \> ULN then use \> 2 \*PreRx. Glucose Fasting: \<0.9\*LLN or \> 1.5\*ULN or if PreRx \< LLN then use \< 0.8\*PreRx or \> ULN, if PreRx \> ULN then use \>2.0\*PreRx. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) ± 2days.

Time frame:
Day 1 to last dose of study drug plus 2 days
Reported as:
Number · participants
Number of Participants With Marked Abnormalities in Glucose, Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests During the Treatment Period in Treated Participants
participantsApixaban 2.5 mgEnoxaparin 40 mg
Glucose Fasting <0.9*LLN (N=284,287)53
Glucose Fasting > 1.5*ULN (N=284,287)3930
Total Protein < 0.9 *LLN (N=2864, 2890)7851
Total Protein > 1.1*ULN (N=2864, 2890)168
Creatine kinase >5*ULN U/L(N=2856, 2888)810
Uric acid > 1.5* ULN (N=2862, 2889)4744
SecondaryIncidence of Events of Special Interest of Adjudicated Myocardial Infarction, Stroke, and Thrombocytopenia During the Treatment Period in Treated Participants

Events of Special Interest include: adjudicated thrombocytopenia, adjudicated myocardial infarction (MI), adjudicated stroke, and adjudicated MI or stroke. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants). Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs.

Time frame:
Day 1 to last dose of study drug plus 2 days
Reported as:
Number · Event Rate (%)
Incidence of Events of Special Interest of Adjudicated Myocardial Infarction, Stroke, and Thrombocytopenia During the Treatment Period in Treated Participants
Event Rate (%)Apixaban 2.5 mgEnoxaparin 40 mg
MI or stoke (N=3183, 3216)0.38 (0.21 to 0.67)0.37 (0.21 to 0.66)
MI (N=3184, 3217)0.22 (0.10 to 0.47)0.12 (0.04 to 0.34)
Stroke (N=3183, 3216)0.16 (0.06 to 0.38)0.25 (0.12 to 0.50)
Thrombocytopenia (N=3184, 3217)0.19 (0.08 to 0.42)0.09 (0.02 to 0.29)
Statistical analysis
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Adjusted event rate difference: -0.00 · 95% CI -0.30 to 0.29stratification factor: previous VTE (yes, no), and active or previous cancer (yes, no).
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Adjusted difference of event rates: 0.09 · 95% CI -0.11 to 0.30stratification factor: previous VTE (yes, no), and active or previous cancer (yes, no).
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Adjusted difference in event rates: -0.10 · 95% CI -0.32 to 0.12
  • Apixaban 2.5 mg vs Enoxaparin 40 mg · Adjusted difference in event rates: 0.09 · 95% CI -0.09 to 0.28stratification factor: previous VTE (yes, no), and active or previous cancer (yes, no).
SecondaryNumber of Participants With Events of Special Interest for Liver Function and Neurology During Treatment Period in Treated Participants With Available Measurements

Special interest include: liver function test increases, AEs related to liver function, and neurologic AEs. Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drug when summarizing AEs and through 30 days after the last dose when summarizing SAEs.

Time frame:
Day 1 to last dose of study drug plus 2 days (AEs) and plus 30 days (SAEs)
Reported as:
Number · participants
Number of Participants With Events of Special Interest for Liver Function and Neurology During Treatment Period in Treated Participants With Available Measurements
participantsApixaban 2.5 mgEnoxaparin 40 mg
Neurologic AEs4542
Neurologic SAEs51
Liver-related AEs127142
Liver-related SAEs912
SecondaryNumber of Participants With Liver-Related Elevations During the Treatment Period in Treated Participants

Liver function tests: Alanine aminotransferase (ALT) U/L; Aspartate aminotransferase (AST) U/L; Alkaline phosphatase U/L; Total Bilirubin (TBili) mg/dL. Elevations consist of \>3\*Upper Limit of Normal (ULN) for ALT and AST and elevation of \>2\*ULN for Bilirubin.

Time frame:
Day 1 to last dose of study drug plus 2 days
Reported as:
Number · participants
Number of Participants With Liver-Related Elevations During the Treatment Period in Treated Participants
participantsApixaban 2.5 mgEnoxaparin 40 mg
AST Elevation >3*ULN (N=2831, 2863)2328
ALT Elevation >3*ULN (N=2827, 2861)2232
AST + ALT >3*ULN on same date (N= 2827, 2861)1413
TBili >2*ULN (N= 2853, 2884)1314
ALT or AST >3*ULN + TBili >2*ULN (N=2818,2855)22
ALT>3*ULN + TBili >2*ULN (N=2817, 2853)02

Adverse events

Collected over Day 1, first dose of study drug, to last dose of study drug plus 2 days (AEs), plus 30 days (SAEs, Deaths).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apix 2.5mg BID—611/3,184 (19.2%)0/3,184 (0%)
Enox 40mg QD—601/3,217 (18.7%)0/3,217 (0%)
Most frequent serious events
Showing 10 of 454
Most frequent serious events
EventApix 2.5mg BIDEnox 40mg QD
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders91/3184103/3217
PneumoniaInfections and infestations54/318440/3217
Cardiac failureCardiac disorders50/318428/3217
Respiratory failureRespiratory, thoracic and mediastinal disorders26/318434/3217
Cardiac failure congestiveCardiac disorders31/318432/3217
Deep vein thrombosisVascular disorders25/318422/3217
Acute respiratory failureRespiratory, thoracic and mediastinal disorders17/318420/3217
Pulmonary embolismRespiratory, thoracic and mediastinal disorders18/318420/3217
AsthmaRespiratory, thoracic and mediastinal disorders7/318419/3217
Atrial fibrillationCardiac disorders14/318415/3217

Baseline characteristics

Randomized Participants

Age, Continuous
Age, Continuous(years)Apixaban 2.5 mgEnoxaparin 40 mgTotal
Median68.0 (40 to 101)67.0 (40 to 98)67.0 (40 to 101)
Age, Customized
Age, Customized(participants)Apixaban 2.5 mgEnoxaparin 40 mgTotal
Less than (<) 65 years140114112812
Greater than, equal to (>=) 65 and < 75 years8908841774
>= 75 years9649781942
Sex: Female, Male
Sex: Female, Male(Participants)Apixaban 2.5 mgEnoxaparin 40 mgTotal
Female162916963325
Male162615773203
Region of Enrollment
Region of Enrollment(participants)Apixaban 2.5 mgEnoxaparin 40 mgTotal
United States6256201245
Philippines222244
Hong Kong262652
Taiwan8715
Spain5150101
Ukraine270276546
Chile6565130
Israel168168336
Russian Federation6326321264
Colombia101424
Italy353469
India198202400
France203200403
Malaysia91120
Denmark4954103
Australia5149100
Peru119121240
South Africa5248100
Netherlands101
Korea, Republic of333366
Turkey91019
Austria5712
United Kingdom195194389
Hungary181634
Czech Republic5356109
Mexico5859117
Canada454792
Argentina7877155
Brazil414586
Belgium212243
Poland5760117
Singapore81220
Norway325
Germany353267
Sweden224
Participants with Risk Factors
Participants with Risk Factors(participants)Apixaban 2.5 mgEnoxaparin 40 mgTotal
Previous Venous Thromboembolism (VTE)141124265
Estrogenic Hormone Therapy492776
History of Malignancy312320632
Chronic Heart Failure153115373068
08

Study locations

297 sites
  • University Of Alabama At Birmingham Hospital
    Birmingham, Alabama 35294, United States
  • Heart Center Research, Llc
    Huntsville, Alabama 35801, United States
  • Arizona Pulmonary Specialists, Ltd.
    Phoenix, Arizona 85013, United States
  • Az Pulmonary Specialists Ltd
    Scottsdale, Arizona 85258, United States
  • Fort Smith Lung Center
    Fort Smith, Arkansas 72901, United States
  • Scripps Clinic/Scripps Health And Green Hospital
    La Jolla, California 92037, United States
  • Va Long Beach Healthcare System
    Long Beach, California 90822, United States
  • Univ. Of Southern Calif. /Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Dr. Felt Medical Office
    Oakland, California 94609, United States
  • Stanford University
    Stanford, California 94305, United States
  • Yale University School Of Medicine
    New Haven, Connecticut 06510, United States
  • Norwalk Hospital
    Norwalk, Connecticut 06856, United States
  • George Washington University
    Washington, District of Columbia 20037, United States
  • Florida Hospital Celebration Health
    Celebration, Florida 34747, United States
  • Research Alliance, Inc.
    Clearwater, Florida 33756, United States
  • Jacksonville Center For Clinical Research
    Jacksonville, Florida 32216, United States
  • Pensacola Lung Group
    Pensacola, Florida 32504, United States
  • Indian River Med. Ctr.
    Vero Beach, Florida 32960, United States
  • Atlanta Institute For Medical Research, Inc
    Atlanta, Georgia 30030, United States
  • Pulmonary & Critical Care Of Atlanta
    Atlanta, Georgia 30342, United States
  • Idaho Falls Infectious Diseases, Pllc
    Idaho Falls, Idaho 83404, United States
  • West Suburban Hospital
    Oak Park, Illinois 60302, United States
  • Infectious Disease Of Indiana Psc
    Carmel, Indiana 46032, United States
  • Cotton-O-Neil Clinical Research Center
    Topeka, Kansas 66604, United States
  • Louisiana State University Health Sciences Center-Shreveport
    Shreveport, Louisiana 71103, United States
  • Johns Hopkins University School Of Medicine
    Baltimore, Maryland 21205, United States
  • Franklin Square Hospital
    Baltimore, Maryland 21237, United States
  • Henry Ford Hospital, Transplant Institute
    Detriot, Michigan 48202, United States
  • University Of Missouri-Columbia
    Columbia, Missouri 65212, United States
  • Mercury Street Medical Group, Pllc
    Butte, Montana 59701, United States
  • Creighton University Medical Center
    Omaha, Nebraska 68131, United States
  • Morristown Memorial Hospital
    Mornstown, New Jersey 07962, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • Staten Island University Hospital
    Staten Island, New York 10305, United States
  • Mission Hospital, Inc
    Asheville, North Carolina 28801, United States
  • South Oklahoma Heart Research
    Oklahoma City, Oklahoma 73135, United States
  • Lehigh Valley Hospital
    Allentown, Pennsylvania 18103, United States
  • The Milton S Hershey Medical Center Of Penn. State Univ.
    Hershey, Pennsylvania 17033, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Palmetto Nephrology Pa
    Orangeburg, South Carolina 29118, United States
  • S. Carolina Pharmaceutical Research
    Spartanburg, South Carolina 29303, United States
  • Texas Health Presbyterian Dallas
    Dallas, Texas 75231, United States
  • Michael E. De Bakey Veteran Affairs Medical Center
    Houston, Texas 77030, United States
  • Sonterra Clinical Research
    San Antonio, Texas 78205, United States
  • Sonterra Clinical Research
    San Antonio, Texas 78258, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • University Of Utah Medical Center
    Salt Lake City, Utah 84132, United States
  • Mcguire Va Medical Center
    Richmond, Virginia 23249, United States
  • Local Institution
    Ciudad Autonoma Buenos Aires, Buenos Aires C1280AEB, Argentina
  • Local Institution
    Coronel Suarez, Buenos Aires B7540GHD, Argentina
  • Local Institution
    Derqui-Pilar, Buenos Aires B1629ODT, Argentina
  • Local Institution
    La Plata, Buenos Aires 1900, Argentina
  • Local Institution
    Munro, Buenos Aires B1605DSX, Argentina
  • Local Institution
    San Martin, Buenos Aires B1650CSQ, Argentina
  • Local Institution
    Rosario, Santa Fe 2000, Argentina
  • Local Institution
    Rosario, Santa Fe S2002KDS, Argentina
  • Local Institution
    San Miguel De Tucuman, Tucuman T4000JCU, Argentina
  • Local Institution
    Buenos Aires, C1181ACH, Argentina
  • Local Institution
    Cordoba, 5000, Argentina
  • Local Institution
    Cordoba, X5006IKK, Argentina
  • Local Institution
    Corrientes, 3400, Argentina
  • Local Institution
    Concord, New South Wales 2139, Australia
  • Local Institution
    St Leonards, New South Wales 2065, Australia
  • Local Institution
    Kippa Ring, Queensland 4021, Australia
  • Local Institution
    Woolloongabba, Queensland 4102, Australia
  • Local Institution
    Bedford Park, South Australia 5042, Australia
  • Local Institution
    Woodville, South Australia 5011, Australia
  • Local Institution
    Box Hill, Victoria 3128, Australia
  • Local Institution
    Parkville, Victoria 3050, Australia
  • Local Institution
    Ringwood East, Victoria 3135, Australia
  • Local Institution
    Graz, 8036, Austria
  • Local Institution
    Wien, 1090, Austria
  • Local Institution
    Ottignies, Waals-Brabant 1340, Belgium
  • Local Institution
    Antwerpen, 2060, Belgium
  • Local Institution
    Brasschaat, 2930, Belgium
  • Local Institution
    Bruxelles, 1070, Belgium
  • Local Institution
    Huy, 4500, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Belo Horizonte, Minas Gerais 30150, Brazil
  • Local Institution
    Curitiba, Parana 80010, Brazil
  • Local Institution
    Curitiba, Parana 80810, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 90020, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 91430, Brazil
  • Local Institution
    Botucatu, Sao Paulo 18618, Brazil
  • Local Institution
    Campinas, Sao Paulo 13059, Brazil
  • Local Institution
    Sao Jose Do Rio Preto, Sao Paulo 15091, Brazil
  • Local Institution
    Sao Paulo, 04012, Brazil
  • Local Institution
    Sao Paulo, 04020, Brazil
  • Local Institution
    Sao Paulo, 04025, Brazil
  • Local Institution
    Sao Paulo, 05403, Brazil
  • Local Institution
    Ajax, Ontario L1S 7K8, Canada
  • Local Institution
    Hamilton, Ontario L8N 3Z5, Canada
  • Local Institution
    Hamilton, Ontario L8N 4A6, Canada
  • Local Institution
    Windsor, Ontario N8X 5A6, Canada
  • Local Institution
    Windsor, Ontario N9A 1C9, Canada
  • Local Institution
    Granby, Quebec J2G 1T7, Canada
  • Local Institution
    Greenfield Park, Quebec J4V 2H1, Canada
  • Local Institution
    Montreal, Quebec H1T 2M4, Canada
  • Local Institution
    Montreal, Quebec H2L 4M1, Canada
  • Local Institution
    Montreal, Quebec H3T 1E2, Canada

Showing the first 100 of 297 sites across 35 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chi G, Goldhaber SZ, Kittelson JM, Turpie AGG, Hernandez AF, Hull RD, Gold A, Curnutte JT, Cohen AT, Harrington RA, Gibson CM. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. J Thromb Haemost. 2017 Oct;15(10):1913-1922. doi: 10.1111/jth.13783. Epub 2017 Sep 4. PubMed 28762617 ↗
  • Marszalek J, Mehrsefat S, Chi G. The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis. Expert Rev Hematol. 2017 Aug;10(8):679-684. doi: 10.1080/17474086.2017.1343662. Epub 2017 Jun 21. PubMed 28617144 ↗
  • Sharma A, Chatterjee S, Lichstein E, Mukherjee D. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? J Thromb Haemost. 2012 Oct;10(10):2053-60. doi: 10.1111/j.1538-7836.2012.04874.x. PubMed 22863355 ↗
  • Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011 Dec 8;365(23):2167-77. doi: 10.1056/NEJMoa1110899. Epub 2011 Nov 13. PubMed 22077144 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2007
First posted
Apr 5, 2007
Start
Jun 2007
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
May 20, 2014
Last update
Dec 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00457002
Responsible party
Sponsor
First posted
Apr 5, 2007
Start date
Jun 2007
Primary completion
May 2011
Completion
May 2011
Results posted
May 20, 2014
Last update
Dec 8, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion